Nautilus Biotechnology reports Q3 EPS (11c) vs (13c) last year

“In Q3, Nautilus maintained disciplined execution and delivered meaningful progress across our platform, strategic collaborations, and operational initiatives-all aligned with our path toward commercialization in late 2026,” said Sujal Patel, CEO of Nautilus Biotechnology (NAUT). “Our near-term focus is on the successful launch of our early access program, beginning with Tau proteoforms in the first half of 2026 and expanding to broadscale capabilities later in the year. These milestones are critical steps toward enabling customers to experience the value of our technology and advancing toward full commercial availability.”